Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A

Anhui Sunhere Pharmaceutical Excipients Co., Ltd. Class A

SSZSE:300452
11.38
CNY
-0.08
(-0.70%)
0.69EPS
18.26P/E
3.11BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.21
1.35
1.15
1.23
1.44
1.81
1.99
2.31
2.63
3.02
3.58
3.77
4.01
4.35
Basic EPS, GAAP
0.2
0.2
0.2
0.21
0.21
0.3
0.36
0.41
0.38
0.56
0.69
0.51
0.75
0.73
Free Cash Flow per Basic Share
-0.07
0.14
0.15
0.17
0.16
-0.03
0.08
0.28
0.31
0.28
0.33
0.39
0.64
- -
Dividend per Share
0.04
0.04
0.03
0.04
0.08
0.1
0.12
0.15
0.2
0.24
0.26
0.25
0.3
0.31
Book Value per Share
0.85
1
1.54
1.71
1.88
2.1
2.23
2.49
2.73
3.08
3.69
3.86
4.29
4.54
Tangible Book Value per Share
0.69
0.86
1.44
1.61
1.52
1.75
1.89
2.15
2.33
2.69
3.3
3.64
4.06
4.2
Basic Weighted Avg Shares
176
177
224
233
236
237
233
230
235
233
234
234
235
233
Sales/Revenue/Turnover
213
239
259
286
339
429
464
531
617
705
839
883
943
1,015
Operating Margin (%)
18.35
14.74
17.35
17.05
16.23
19.31
21.32
20.04
16.08
18.33
20.31
20
20.58
19.88
Depreciation Expense
5
10
11
12
14
16
20
32
35
36
39
51
53
- -
Net Income, GAAP
35
35
44
49
50
70
84
94
89
131
162
119
177
169
Effective Tax Rate (%)
14.14
14.32
14.54
14.47
15.47
14.59
12.66
12.74
11.53
4.01
11.41
15.34
12.84
13
Profit Margin (%)
16.45
14.59
17.1
17.03
14.83
16.36
18.18
17.69
14.47
18.55
19.25
13.53
18.73
16.69
Working Capital
26
53
236
268
259
237
197
273
330
286
666
788
874
917
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
288
299
309
316
Total Equity
149
177
363
403
500
560
597
655
706
789
935
975
1,074
1,132
Return on Invested Capital (%)
23.95
18.13
14.92
11.91
11.26
14.08
15.4
14.49
12.24
16.65
15.88
9.62
12.93
- -
Return on Capital (%)
25.69
21.29
16.39
12.33
10.39
11.81
13.47
14.58
13.13
16.82
15.74
10.27
14.34
- -
Return on Common Equity (%)
25.9
21.4
16.39
12.74
11.93
14.98
16.54
16.91
14.57
19.19
20.34
13.49
18.47
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
20
32
31
LT Borrowings
312
314
316
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
234
234
234
Market Capitalization
3,507
2,738
3,109

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,201
1,232
1,232
Cash, Cash Equivalents & STI
828
859
876
Accounts Receivable, Net
174
158
158
Inventories
90
108
102
Total Current Liabilities
274
322
315
Payables & Accruals
- -
- -
- -
ST Debt
20
32
31
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.58%
10.49%
10.09%
Free Cash Flow
-14.9%
21.01%
67.34%
Net Income, GAAP
17.12%
17.36%
47.84%
Sales/Revenue/Turnover
13.96%
12.29%
6.82%
Total Cash Common Dividend
28.99%
15.86%
21.05%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
238
212
194
238
883
2025
248
223
- -
246
943
2026
261
260
247
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.2
0.12
-0.01
0.51
2025
0.2
0.2
- -
0.19
0.75
2026
0.2
0.21
0.13
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.27
- -
-0.02
0.25
2025
- -
0.31
- -
- -
0.3
2026
- -
0.31
- -
- -
- -

Company Description

CEO
Dao Cai Song
Full Time Employees
1,130
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Huainan Economic and Technological Development Zone, Huainan AN China 232007
IPO Date
May 4, 2015
Business
Anhui Sunhere Pharmaceutical Excipients Co., Ltd. specializes in the research, development, production, and sale of pharmaceutical excipients. The company manufactures a diverse range of excipients including hypromellose (hydroxypropyl methylcellulose, HPMC) used as film-forming agents and emulsifiers; low-substituted hydroxypropyl cellulose (LHPC); maize starch and corn starch serving as tablet and capsule diluents and disintegrants; magnesium stearate as a lubricant excipient; microcrystalline cellulose; polyacrylic resin IV for gastric-soluble coatings; povidone as a solubility enhancer and film former; silicon dioxide as a flow agent; and additional excipients such as stearic acid, coating powders, resins, and food additives. The company also provides technical support services including formulation development, quality control, stability testing, and customized excipient solutions. Anhui Sunhere primarily serves the pharmaceutical industry across China and exports internationally. Founded in 2001 and headquartered in Huainan, Anhui Province, it is one of China's largest excipient manufacturers and a national R&D base recognized as a high-tech corporation in Anhui Province. In recent developments, Anhui Sunhere has undertaken a strategic capital increase of 92 million yuan into its wholly-owned subsidiary, Hefei Sunhere Pharmaceutical Technology Co., Ltd., to support the construction of a new R&D center and production base in Hefei's High-tech Zone, aiming to enhance innovation and production capacity. The company is actively participating in land acquisition for this project and continuing its expansion of research and production facilities. Additionally, Anhui Sunhere has acquired a 52% stake in Qufu Tianli Medical Supplements to broaden its business scope. The company has also gained recognition for breaking technological monopolies in domestic excipients, challenging Japanese market dominance through innovation. Shareholders plan to reduce their holdings by up to 3% between late 2025 and early 2026. Anhui Sunhere maintains leadership in excipient manufacturing for solid dosage forms in China and is positioned for continued growth through enhanced R&D and strategic investments. Anhui Sunhere operates within the pharmaceutical excipients industry segment, targeting pharmaceutical companies requiring base materials for solid oral dosage forms and other pharmaceutical products. Its product portfolio focuses heavily on cellulose derivatives, starch derivatives, and other performance-enhancing excipients. The company holds various national and provincial innovation awards and participates in the executive director role of the China Pharmaceutical Excipients industry association, underlining its industry influence. This comprehensive product offering and ongoing strategic facility expansion underline Anhui Sunhere Pharmaceutical Excipients Co., Ltd.'s commitment to technological advancement and market leadership in China’s pharmaceutical excipient manufacturing sector. The company’s operations concentrate mainly in China, with exports extending its geographic reach internationally. The firm continues to develop innovative pharmaceutical excipients tailored to evolving industry needs while expanding production capabilities through substantial capital investments in new facilities and subsidiaries. This description is based on the latest publicly available corporate information as of late 2025.